Skip to content
HyperStake UK

Patients Coming Off Weight-Loss Medications Put On Weight Four Times Faster Compared to Dieters

Image of medical syringe and weighing machine
Obesity treatment often requires ongoing approaches.

Fresh analysis reveals that people who come off popular GLP-1 drugs like Wegovy and Mounjaro may regain lost weight far faster than those who stop traditional diet and exercise plans.

Research printed in a major medical journal points out that while overweight individuals frequently drop substantial amounts of their total mass while using the jabs, the mass returns at an average rate of 0.8 kg per month upon discontinuation.

"Individuals purchasing such medications must be cognizant of the potential of fast rebound weight gain when the therapy ends," warns lead investigator Dr. Susan Jebb.

Such speed of recovery implies a return to original mass in about a year and a half.

Comparing Approaches

The analysis, which reviewed 37 of studies involving thousands of patients, compared the effects of these new drugs with other pills.

Researchers point out that people who lose weight through dieting generally see a less rapid weight regain—around 100 grams monthly—once they finish.

The Reason for the Rapid Rebound

Doctors suggest the mechanism of the injections accounts for the heightened rebound.

The injections copy a natural hormone called GLP-1, which controls feelings of fullness.

"Sustained high doses of GLP-1 concentrations several times higher than normal might result in the body to produce less of its own natural hormone, and could diminish sensitivity to its effects," noted Dr. Adam Collins, a dietetics researcher.

"Withdrawal of this medication leads to hunger is unsuppressed, making excessive eating much more probable."

A Lifelong Issue?

Health authorities recommend the injections for individuals with obesity-related medical conditions, accompanied by prescribed diet and exercise modifications.

Professionals contend that, considering the likelihood of weight regain, the treatment is often ongoing.

This view is reinforced by drug manufacturers, who state that the findings "underscore the long-term nature of excess weight," akin to managing diseases like high blood pressure.

User Experiences

Individuals who have come off the jabs describe a sudden resurgence of cravings.

"I experienced a trigger activating and you're instantly starving," recalled an individual.

This challenge is compounded if users have not established sustainable dietary or behavioural modifications during therapy.

Significant Adoption

Figures indicate that a significant number of adults in the UK have tried these injections in the last 12 months, with desire remaining high.

  • Use is more common among women than men.
  • The 40s and 50s demographic shows the highest level of interest.
  • Many access the medications through private prescriptions rather than public health services.

Ultimately, clinicians emphasize that while these medications are potent tools for weight loss, they are not a standalone solution and maintained weight loss hinges on integrated lifestyle support.

JY
About the author

Justin Young

A blockchain strategist with over a decade in fintech, specializing in decentralized systems and crypto market analysis.

HyperStake UK

Type to search articles.